Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of ASP6294 in Healthy Subjects
NCT02681861Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2016
- Primary completion
- Dec 2016
- Modality
- Antibody Conjugates, Fab Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP6294 in osteoarthritis (OA) and chronic pain (2 arms), sponsored by Astellas Pharma. Primary endpoints: Nature, frequency and severity of Adverse Events (AEs) up to 120 Days, Vital signs up to 120 Days and 5 more. Started Jan 2016; status: completed.
02
Drugs
ASP6294
03
Conditions
osteoarthritis (OA)chronic pain
Beyond the preview
Go deeper on NCT02681861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681861.